Cellectis Reports Q2 2025 Financial Results and Business Update, Plans R&D Day for Investors, and Appoints New Board Member.
ByAinvest
Monday, Aug 4, 2025 4:32 pm ET1min read
CLLS--
Cellectis reports Q2 2025 financial results and updates on its activities, including plans to hold an R&D Day in New York on October 16, 2025, to present phase 1 data and development strategy for lasme-cel (UCART22) in relapsed/refractory B-cell acute lymphoblastic leukemia (LAL-B r/r). The company also announced the nomination of André Muller as an administrator to its board of directors and reported a cash, cash equivalents and term deposits balance of $230 million as of June 30, 2025.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet